Overview

* NAI fiscal Q1 2026 net loss narrows to $0.3 mln from $2.0 mln last year

* Company's Q1 net sales rise 13.8% to $37.7 mln, driven by private-label sales

* CarnoSyn® beta-alanine revenue declines 33.9% due to decreased raw material orders

Outlook

* Company anticipates net loss in first half, net income in second half of fiscal 2026

* NAI focuses on expanding client relationships and TriBsyn™ adoption

* Company addressing supply chain disruptions for anticipated sales growth

Result Drivers

* PRIVATE-LABEL SALES - Increased orders from existing and new customers drove a 17.7% rise in private-label contract manufacturing sales

* GROSS PROFIT IMPROVEMENT - Improved factory utilization and lower volume rebates contributed to higher gross profit

* CARNOSYN® REVENUE DECLINE - Decreased raw material orders led to a 33.9% drop in CarnoSyn® beta-alanine revenue

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q1 Sales $37.73

mln

Q1 Net -$291,00

Income 0

Q1 Gross $4.40

Profit mln

Q1 $284,000

Operatin

g Income

Q1 -$199,00

Pretax 0

Profit

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)